Full Press Release Details
Reports Second Quarter 2020 Financial and Operational Results
Md., August 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation
vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter
ended June 30, 2020.
"Novavax' unprecedented development
activities for NVX-CoV2373 and progress continued through the second quarter," said Stanley C. Erck, President and Chief
Executive Officer of Novavax. "Since identifying a candidate vaccine to address the COVID-19 pandemic in March, we've
secured significant funding, implemented global manufacturing capacity and completed and reported our successful Phase 1 trial.
We've also expanded our senior leadership team to advance our efforts to bring NVX-CoV2373 to market as rapidly as possible
and grow our infrastructure to support commercial stage operations."
Second Quarter 2020 and Recent Highlights
Financial Results for the Three and
Six Months Ended June 30, 2020
Novavax reported a net loss of $17.5 million,
or $0.30 per share, for the second quarter of 2020, compared to a net loss of $39.6 million, or $1.69 per share, for the second
quarter of 2019. For the six months ended June 30, 2020, the net loss was $43.4 million, or $0.84 per share, compared to a net
loss of $82.8 million, or $3.77 per share, for the same period in 2019.
Novavax revenue in the second quarter of
2020 was $35.5 million, compared to $3.4 million in the same period in 2019. This significant increase was due to increased development
activities relating to NVX-CoV2373 under the CEPI agreement.
Research and development expenses increased
15% to $34.8 million in the second quarter of 2020, compared to $30.4 million in the same period in 2019. The increase was primarily
due to increased development activities relating to NVX-CoV2373 under the CEPI agreement, partially offset by decreased employee-related
and other costs and development activities of ResVax as compared to the same period in 2019.
General and administrative expenses increased
84% to $17.7 million in the second quarter of 2020, compared to $9.6 million for the same period in 2019. This increase was primarily
due to increased professional fees relating to the Novavax CZ acquisition and supporting our NVX-CoV2373 program and increased
employee-related expenses.
As of June 30, 2020, Novavax had $609.5
million in cash, cash equivalents, marketable securities and restricted cash, compared to $82.2 million as of December 31, 2019.
Net cash provided by operating activities for the first six months of 2020 was $92.5 million, compared to net cash used in operating
activities was $80.6 million for same period in 2019.
Novavax has continued to strengthen its
balance sheet. Recent activities include:
Novavax will host its quarterly conference
call today at 4:30 p.m. ET. The dial-in numbers for the conference call are (866) 923-9367 (Domestic) or (707) 287-9331 (International),
passcode 3048947. A replay of the conference call will be available starting at 7:30 p.m. ET on August 10, 2020 until 7:30 p.m.
ET on August 17, 2020. To access the replay by telephone, dial (855) 859-2056 (Domestic) or (404) 537-3406 (International) and
use passcode 3048947.
conference call can also be accessed via a link on the home page of the Novavax website (novavax.com) or through the "For
Investors"/"Events" tab on the Novavax website. A replay of the webcast will be available on the Novavax website
until November 10, 2020.
is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373
was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S)
protein and contains Novavax' patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate
high levels of neutralizing antibodies. In preclinical trials, NVX-CoV2373 demonstrated indication of antibodies that block binding
of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In its Phase 1
portion of the Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated
and elicited robust antibody responses numerically superior to that seen in human convalescent sera. Novavax
was awarded $1.6 billion by the federal government as part of Operation Warp Speed (OWS), a U.S. government program to deliver
millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population. The OWS funding is being used by Novavax to
complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and
deliver 100 million doses of NVX-CoV2373 beginning as early as late 2020. The Coalition for Epidemic Preparedness Innovations (CEPI)
is also investing up to $388 million, and Department of Defense (DoD) is investing up to $60 million of funding to advance clinical
development of NVX-CoV2373.
NanoFlu is a recombinant
hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu
uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. NanoFlu contains
Novavax' patented saponin-based Matrix-M adjuvant.
patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting
cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
(Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development,
and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for
NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NVX-CoV2373 was generally well-tolerated
and elicited robust antibody responses numerically superior to that seen in human convalescent sera in its Phase 1 portion of the
Phase 1/2 clinical trial. NanoFlu , its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal
Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M
adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator
of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to
efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
For more information, visit www.novavax.com
and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
Statements herein relating to the future
of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that
these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially
from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk
Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 8-K
for the period ended June 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place
considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with
the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this
press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements.
Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors,
and others should give careful consideration to these risks and uncertainties.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share information)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenue | $ | 35,538 | $ | 3,357 | $ | 38,915 | $ | 7,339 | ||||||||
| Expenses: | ||||||||||||||||
| Research and development | 34,846 | 30,417 | 51,741 | 65,890 | ||||||||||||
| General and administrative | 17,719 | 9,606 | 27,098 | 18,338 | ||||||||||||
| Total expenses | 52,565 | 40,023 | 78,839 | 84,228 | ||||||||||||
| Loss from operations | (17,027 | ) | (36,666 | ) | (39,924 | ) | (76,889 | ) | ||||||||
| Interest income (expense), net | (3,106 | ) | (2,929 | ) | (6,074 | ) | (5,912 | ) | ||||||||
| Other income (expense) | 2,612 | (8 | ) | 2,613 | (20 | ) | ||||||||||
| Net loss | $ | (17,521 | ) | $ | (39,603 | ) | $ | (43,385 | ) | $ | (82,821 | ) | ||||
| Basic and diluted net loss per share | $ | (0.30 | ) | $ | (1.69 | ) | $ | (0.84 | ) | $ | (3.77 | ) | ||||
| Basic and diluted weighted average | ||||||||||||||||
| number of common shares outstanding | 58,618 | 23,473 | 51,401 | 21,966 |
SELECTED CONSOLIDATED BALANCE SHEET DATA
| June 30, 2020 | December 31, 2019 | |||||||
| (unaudited) | ||||||||
| Cash and cash equivalents | $ | 424,395 | $ | 78,823 | ||||
| Marketable securities | 77,902 | -- | ||||||
| Total restricted cash | 107,179 | 3,357 | ||||||
| Total current assets | 636,381 | 97,247 | ||||||
| Working capital | 423,050 | 71,452 | ||||||
| Total assets | 932,227 | 172,957 | ||||||
| Notes payable | 321,323 | 320,611 | ||||||
| Total stockholders' equity (deficit) | 184,526 | (186,017 | ) |
Silvia Taylor and Erika Trahan
Brandzone/KOGS Communication